Why is INmune Bio, Inc. ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
0.98%
EBIT Growth (5y)
-216.31%
EBIT to Interest (avg)
-25.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
37.76%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.96
EV to EBIT
-3.80
EV to EBITDA
-3.80
EV to Capital Employed
15.04
EV to Sales
157.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-396.14%
ROE (Latest)
-137.49%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Movement
12What is working for the Company
NET SALES(HY)
At USD 0.05 MM has Grown at 257.14%
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -114.05 %
OPERATING PROFIT(Q)
Highest at USD -8.06 MM
PRE-TAX PROFIT(Q)
Highest at USD -7.94 MM
NET PROFIT(Q)
Highest at USD -7.94 MM
-6What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -32.2 MM
ROCE(HY)
Lowest at -168.34%
EPS(Q)
Lowest at USD -1.05
Here's what is working for INmune Bio, Inc.
Net Sales
At USD 0.05 MM has Grown at 257.14%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Profit
Highest at USD -8.06 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -7.94 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -7.94 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Debt-Equity Ratio
Lowest at -114.05 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for INmune Bio, Inc.
Operating Cash Flow
Lowest at USD -32.2 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
EPS
Lowest at USD -1.05
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)






